{"id":22256,"date":"2025-10-29T17:28:31","date_gmt":"2025-10-29T10:28:31","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=22256"},"modified":"2025-10-29T17:28:31","modified_gmt":"2025-10-29T10:28:31","slug":"zuclopenthixol-tablets","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/zuclopenthixol-tablets\/","title":{"rendered":"Zuclopenthixol Tablets"},"content":{"rendered":"

Action and use<\/strong><\/p>\n

Dopamine receptor antagonist; neuroleptic.<\/p>\n

DEFINITION<\/h2>\n
Zuclopenthixol Tablets contain Zuclopenthixol Hydrochloride.<\/p>\n
The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n
Content of zuclopenthixol, C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS<\/strong><\/p>\n}}}
95.0 to 105.0% of the stated amount.<\/p>\n
IDENTIFICATION<\/h2>\n
A. To a quantity of the powdered tablets containing the equivalent of 20 mg of zuclopenthixol add 40 mL of 0.1M hydrochloric acid, heat on a water bath for 30 minutes, shaking occasionally, cool, dilute to 200 mL with water and shake thoroughly. Centrifuge a portion of the resulting solution and dilute 20 mL of the supernatant liquid to 200 mL with water. Measure the absorbance, Appendix II B at 230 nm using 0.002M hydrochloric acid in the reference cell. The light absorption, Appendix II B, in the range 205 to 350 nm of a 0.0015% w\/v solution in ethanol (96%) exhibits maxima at 230, 268 and 325 nm.<\/p>\n
B. In the Assay, the chromatogram obtained with solution (1) shows a peak with the same retention time as the principal peak in the chromatogram obtained with solution (2).<\/p>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
Comply with the dissolution test for tablets and capsules, Appendix XII B1. Carry out the procedure protected from light.<\/p>\n
TEST CONDITIONS<\/h4>\n
(a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.<\/p>\n
(b) Use 900 mL of 0.01M hydrochloric acid, at a temperature of 37\u00b0, as the medium.<\/p>\n
PROCEDURE<\/h4>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions<\/p>\n
(1) After 30 minutes withdraw a sample of the medium, filter and dilute with the dissolution medium, if necessary, to produce a solution expected to contain the equivalent of 0.0002% w\/v of zuclopenthixol.<\/p>\n
(2) 0.00024% w\/v of zuclopenthixol hydrochloride BPCRS in the dissolution medium.<\/p>\n
(3) 0.002% w\/v each of zuclopenthixol hydrochloride BPCRS and trans-clopenthixol hydrochloride BPCRS (impurity B) in solution A.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
(a) Use a stainless steel column (15 cm \u00d7 2.1 mm) packed with octylsilyl silica gel for chromatography (3.5 \u03bcm) (Symmetry Shield RP18 is suitable).<\/p>\n
(b) Use isocratic elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 0.6 mL per minute.<\/p>\n
(d) Use a column temperature maintained at 40\u00b0.<\/p>\n
(e) Use a detection wavelength of 270 nm.<\/p>\n
(f) Inject 250 \u03bcL of each solution.<\/p>\n
(g) allow the chromatography to proceed for 1.5 times the retention time of zuclopenthixol (retention time about 6 miuntes).<\/p>\n
MOBILE PHASE<\/h4>\n
2 volumes of trifluoroacetic acid, 9 volumes of acetonitrile and 41 volumes of water.<\/p>\n
SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n
DETERMINATION OF CONTENT<\/h4>\n
Calculate the total content of zuclopenthixol, C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n}}}}}}
LIMITS<\/h4>\n
The amount of zuclopenthixol released is not less than 75% (Q) of the stated amount.<\/p>\n
Related substances<\/h3>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions protected from light.<\/p>\n
Solution A 18 volumes of acetonitrile and 82 volumes of water.<\/p>\n
(1) Shake a quantity of the powdered tablets containing the equivalent of 25 mg of zuclopenthixol with 5 mL of Solution A with the aid of ultrasound. Add 15 mL of Solution A, place in a water bath for 20 minutes, allow to cool and dilute to 25 mL with solution A.<\/p>\n
(2) Dilute 1 volume of solution (1) to 100 volumes with solution A, further dilute 1 volume of this solution to 5 volumes with solution A.<\/p>\n
(3) Dilute 3 volumes of solution (1) to 100 volumes with solution A.<\/p>\n
(4) 0.002% w\/v each of zuclopenthixol hydrochloride BPCRS and trans-clopenthixol hydrochloride BPCRS (impurity B) in solution A.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
(a) Use a stainless steel column (5 cm \u00d7 2.1 mm) packed with octadecylsilyl silica gel for chromatography (3.5 \u03bcm) (Symmetry Shield RP18 is suitable).<\/p>\n
(b) Use gradient elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 0.6 ml per minute.<\/p>\n
(d) Use a column temperature 40\u00b0.<\/p>\n
(e) Use a detection wavelength of 270 nm.<\/p>\n
(f) Inject 5 \u03bcL of each solution.<\/p>\n
MOBILE PHASE<\/h4>\n
Mobile phase A: 1 volume of trifluoroacetic acid and 25 volumes of water.<\/p>\n
Mobile phase B: 1 volume of trifluoroacetic acid and 25 volumes of acetonitrile.<\/p>\n
Mobile phase C: methanol.<\/p>\n\n\n\n\n\n\n\n
Time (Minutes)<\/strong><\/td>\n Mobile phase A (% v\/v)<\/strong><\/td>\n Mobile phase A (% v\/v)<\/strong><\/td>\n Mobile phase A (% v\/v)<\/strong><\/td>\n Comment<\/strong><\/td>\n<\/tr>\n
0-8<\/td>\n 82<\/td>\n 18<\/td>\n 0<\/td>\n isocratic<\/td>\n<\/tr>\n
8-17<\/td>\n 82\u21925<\/td>\n 18\u219210<\/td>\n 0\u219285<\/td>\n linear gradient<\/td>\n<\/tr>\n
17-19<\/td>\n 5\u219282<\/td>\n 10\u219218<\/td>\n 85\u21920<\/td>\n linear gradient<\/td>\n<\/tr>\n
19-30<\/td>\n 82<\/td>\n 18<\/td>\n 0<\/td>\n re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
When the chromatograms are recorded under the prescribed conditions, the retention times relative to zuclopenthixol (retention time about 6 minutes) are: impurity A, about 0.1; trans-clopenthixol hydrochloride, about 1.2.<\/p>\n
SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n
LIMITS<\/h4>\n
In the chromatogram obtained with solution (1):<\/p>\n
The area of any peak due to trans-zuclopenthixol is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (3%).<\/p>\n
The area of any peak due to zuclopenthixol impurity A is not greater than 1.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.3%).<\/p>\n
The area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%).<\/p>\n
The sum of the areas of any secondary peak, excluding trans-clopenthixol hydrochloride, is not greater than 5 times the area of the principal peak in the chromatogram obtained with solution (2) (1%).<\/p>\n
Disregard any peak with an area of less than half the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).<\/p>\n
ASSAY<\/h2>\n
Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions protected from light.<\/p>\n
Solution A: 18 volumes of acetonitrile and 82 volumes of water.<\/p>\n
(1) To a quantity of the powdered tablets containing the equivalent of 25 mg of zuclopenthixol add 50 mL of solution A and mix with the aid of ultrasound. Add 150 mL of solution A and place in a water bath for 20 minutes, allow to cool and dilute to 250 mL with solution A.<\/p>\n
(2) 0.012% w\/v of zuclopenthixol hydrochloride BPCRS in solution A.<\/p>\n
(3) 0.002% w\/v each of zuclopenthixol hydrochloride BPCRS and trans-clopenthixol hydrochloride BPCRS (impurity B) in solution A.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
The chromatographic conditions described under the Dissolution may be used, with an injection volume of 5\u03bcL.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n
DETERMINATION OF CONTENT<\/h3>\n
Calculate the total content of zuclopenthixol, C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n}}}}}}
LABELLING<\/h2>\n
The quantity of active ingredient is stated in terms of the equivalent amount of zuclopenthixol.<\/p>\n
IMPURITIES<\/h2>\n
The impurities limited by the requirements of this monograph include those shown under Zuclopenthixol Hydrochloride.<\/p>\n","protected":false},"excerpt":{"rendered":"
Action and use Dopamine receptor antagonist; neuroleptic. DEFINITION Zuclopenthixol Tablets contain Zuclopenthixol Hydrochloride. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of zuclopenthixol, C22H25ClN2OS 95.0 to 105.0% of the stated amount. IDENTIFICATION A. To a quantity of the powdered tablets containing the equivalent of 20 mg of zuclopenthixol…<\/p>\n","protected":false},"author":4,"featured_media":22267,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-22256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=22256"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22256\/revisions"}],"predecessor-version":[{"id":22269,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22256\/revisions\/22269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/22267"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=22256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=22256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=22256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time (Minutes)<\/strong><\/td>\n	Mobile phase A (% v\/v)<\/strong><\/td>\n	Mobile phase A (% v\/v)<\/strong><\/td>\n	Mobile phase A (% v\/v)<\/strong><\/td>\n	Comment<\/strong><\/td>\n<\/tr>\n
0-8<\/td>\n	82<\/td>\n	18<\/td>\n	0<\/td>\n	isocratic<\/td>\n<\/tr>\n
8-17<\/td>\n	82\u21925<\/td>\n	18\u219210<\/td>\n	0\u219285<\/td>\n	linear gradient<\/td>\n<\/tr>\n
17-19<\/td>\n	5\u219282<\/td>\n	10\u219218<\/td>\n	85\u21920<\/td>\n	linear gradient<\/td>\n<\/tr>\n
19-30<\/td>\n	82<\/td>\n	18<\/td>\n	0<\/td>\n	re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n When the chromatograms are recorded under the prescribed conditions, the retention times relative to zuclopenthixol (retention time about 6 minutes) are: impurity A, about 0.1; trans-clopenthixol hydrochloride, about 1.2.<\/p>\n SYSTEM SUITABILITY<\/h4>\n The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n LIMITS<\/h4>\n In the chromatogram obtained with solution (1):<\/p>\n The area of any peak due to trans-zuclopenthixol is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (3%).<\/p>\n The area of any peak due to zuclopenthixol impurity A is not greater than 1.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.3%).<\/p>\n The area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%).<\/p>\n The sum of the areas of any secondary peak, excluding trans-clopenthixol hydrochloride, is not greater than 5 times the area of the principal peak in the chromatogram obtained with solution (2) (1%).<\/p>\n Disregard any peak with an area of less than half the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).<\/p>\n ASSAY<\/h2>\n Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions protected from light.<\/p>\n Solution A: 18 volumes of acetonitrile and 82 volumes of water.<\/p>\n (1) To a quantity of the powdered tablets containing the equivalent of 25 mg of zuclopenthixol add 50 mL of solution A and mix with the aid of ultrasound. Add 150 mL of solution A and place in a water bath for 20 minutes, allow to cool and dilute to 250 mL with solution A.<\/p>\n (2) 0.012% w\/v of zuclopenthixol hydrochloride BPCRS in solution A.<\/p>\n (3) 0.002% w\/v each of zuclopenthixol hydrochloride BPCRS and trans-clopenthixol hydrochloride BPCRS (impurity B) in solution A.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/h3>\n The chromatographic conditions described under the Dissolution may be used, with an injection volume of 5\u03bcL.<\/p>\n SYSTEM SUITABILITY<\/h3>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n DETERMINATION OF CONTENT<\/h3>\n Calculate the total content of zuclopenthixol, C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n}}}}}} LABELLING<\/h2>\n The quantity of active ingredient is stated in terms of the equivalent amount of zuclopenthixol.<\/p>\n IMPURITIES<\/h2>\n The impurities limited by the requirements of this monograph include those shown under Zuclopenthixol Hydrochloride.<\/p>\n","protected":false},"excerpt":{"rendered":" Action and use Dopamine receptor antagonist; neuroleptic. DEFINITION Zuclopenthixol Tablets contain Zuclopenthixol Hydrochloride. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of zuclopenthixol, C22H25ClN2OS 95.0 to 105.0% of the stated amount. IDENTIFICATION A. To a quantity of the powdered tablets containing the equivalent of 20 mg of zuclopenthixol…<\/p>\n","protected":false},"author":4,"featured_media":22267,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-22256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=22256"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22256\/revisions"}],"predecessor-version":[{"id":22269,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22256\/revisions\/22269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/22267"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=22256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=22256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=22256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

TESTS<\/h2>\n

Dissolution<\/h3>\nComply with the dissolution test for tablets and capsules, Appendix XII B1. Carry out the procedure protected from light.<\/p>\n

TEST CONDITIONS<\/h4>\n(a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.<\/p>\n(b) Use 900 mL of 0.01M hydrochloric acid, at a temperature of 37\u00b0, as the medium.<\/p>\n

MOBILE PHASE<\/h4>\n2 volumes of trifluoroacetic acid, 9 volumes of acetonitrile and 41 volumes of water.<\/p>\n

SYSTEM SUITABILITY<\/h4>\nThe test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\nCalculate the total content of zuclopenthixol, C22<\/sub>H25<\/sub>ClN2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C22<\/sub>H25<\/sub>ClN2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n

LIMITS<\/h4>\nThe amount of zuclopenthixol released is not less than 75% (Q) of the stated amount.<\/p>\n

SYSTEM SUITABILITY<\/h4>\nThe test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h3>\nThe chromatographic conditions described under the Dissolution may be used, with an injection volume of 5\u03bcL.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\nCalculate the total content of zuclopenthixol, C22<\/sub>H25<\/sub>ClN2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C22<\/sub>H25<\/sub>ClN2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n

LABELLING<\/h2>\nThe quantity of active ingredient is stated in terms of the equivalent amount of zuclopenthixol.<\/p>\n

Dissolution<\/h3>\n
Comply with the dissolution test for tablets and capsules, Appendix XII B1. Carry out the procedure protected from light.<\/p>\n

TEST CONDITIONS<\/h4>\n
(a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.<\/p>\n
(b) Use 900 mL of 0.01M hydrochloric acid, at a temperature of 37\u00b0, as the medium.<\/p>\n

MOBILE PHASE<\/h4>\n
2 volumes of trifluoroacetic acid, 9 volumes of acetonitrile and 41 volumes of water.<\/p>\n

SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\n
Calculate the total content of zuclopenthixol, C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n}}}}}}

LIMITS<\/h4>\n
The amount of zuclopenthixol released is not less than 75% (Q) of the stated amount.<\/p>\n

SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h3>\n
The chromatographic conditions described under the Dissolution may be used, with an injection volume of 5\u03bcL.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks corresponding to zuclopenthixol and trans-clopenthixol hydrochloride is at least 2.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\n
Calculate the total content of zuclopenthixol, C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in the medium from the chromatograms obtained and the declared content of C_{22<\/sub>H_{25<\/sub>ClN_{2<\/sub>OS, in zuclopenthixol hydrochloride BPCRS.<\/p>\n}}}}}}

LABELLING<\/h2>\n
The quantity of active ingredient is stated in terms of the equivalent amount of zuclopenthixol.<\/p>\n